Drug Development

Patient enrollment completed in European phase II trial of Hemopure

Published in Drug Week, May 6th, 2005

Biopure Corporation (BPUR) announced that it has completed enrolling patients in the phase II human clinical trial in Europe evaluating the safety and feasibility of the company's investigational oxygen therapeutic Hemopure [hemoglobin glutamer - 250 (bovine)] in patients undergoing elective coronary angioplasty.

The generation of trial data will conclude at the end of April after all enrolled patients complete the 30-day follow-up period. Biopure is hopeful that the clinical trial investigators will be able to present their preliminary study results in May at the late-breaking session of the EuroPCR conference in Paris.

The clinical trial was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-05-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry